Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company developing immunotherapies for cancer using its proprietary Amphiphile (AMP) technology, which is designed to deliver therapeutic payloads to lymph nodes and stimulate T-cell responses. Its lead candidate, ELI-002 7P, is an… From the company’s description.
In fiscal 2025, Elicio Therapeutics, Inc. reported revenue of $0.41M and a net loss of $39.57M. Operations used $36.95M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Elicio Therapeutics, Inc. does
In the company’s own words
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company developing immunotherapies for cancer using its proprietary Amphiphile (AMP) technology, which is designed to deliver therapeutic payloads to lymph nodes and stimulate T-cell responses. Its lead candidate, ELI-002 7P, is an off-the-shelf peptide immunotherapy targeting seven KRAS mutations and is being evaluated in a Phase 2 trial for pancreatic ductal adenocarcinoma; the company also studies its potential use in colorectal, lung and other KRAS-driven cancers. Preclinical candidates ELI-007 and ELI-008 target BRAF- and TP53-mutated cancers, respectively. The company’s pipeline also explores AMP applications in combination with CAR-T and TCR-T cell therapies and other immune-modulating approaches. Elicio licenses AMP-related technology from the Massachusetts Institute of Technology and seeks collaborations to advance programs and platform applications. Its website is https://elicio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1601485
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Elicio Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Elicio Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Elicio Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Elicio Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Elicio Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”